Constructing a DNAzyme Delivery and Expression System for Escherichia coli: A Prototype for Phage Therapy

##plugins.themes.bootstrap3.article.main##

  •   Hugo V. C. Oliveira

  •   Spartaco Astolfi-Filho

  •   Edmar V. Andrade

Abstract

Antisense oligonucleotides exhibit high potential for use as therapeutic agents. '10-23' DNAzymes are antisense molecules with a high chemical stability and catalytic efficiency. In the present study, we developed a phagemid containing a DNAzyme expression system regulated by two promoters. One of these promoters, pA1, promotes constitutive expression of Moloney murine leukemia virus reverse transcriptase (MoMuLV-RT). The other promoter, plac, regulates transcription of the RNA substrate from which MoMuLV-RT produces the DNAzyme by reverse transcription. The ftsZ DNAzyme was used to validate this expression system in the phagemid, named pDESCP. ftsZ DNAzyme expression altered the morphological pattern of Escherichia coli from a bacillary to filamentous form. In E. coli FtsZ is the primary component of the cell division apparatus, forming a structure known as Z-ring, which is the place of division. It is suggested that the DNAzyme ftsZ is decreasing the translation of this protein. Delivery of pDESCP into F+ strain of E. coli cells, using VCSM13, and the possible insertion of other DNAzymes into the cassette makes this phagemid an important prototype for phage therapy.


Keywords: '10-23' DNAzyme, DNAzyme vectors, Escherichia coli, phagemid transfection

References

Y. Oh and T. G. Park, “siRNA delivery systems for cancer treatment,” Advanced Drug Delivery Reviews, vol. 61, Issue 10, pp.850-862, August 2009.

M. Y. Skoblov, “Prospects of antisense therapy technologies,” Molecular Biology 43, no. 917, December 2009.

L. Tedeschi, C. Lande, A. Cecchettini and L. Citti, “Hammerhead ribozymes in therapeutic target discovery and validation,” Drug Discovery Today Drug discovery today, vol. 14,15-16, pp.776-83, May 2009.

J. Singh, H. Kaur, A. Kaushik and S. Peer, “A review of antisense therapeutic interventions for molecular biological targets in various diseases,” International Journal of Pharmacology, vol. 7, pp. 294-315, May 2011.

J. Li, N. Wang, Q. Luo and L. Wan, “The 10-23 DNA enzyme generated by novel expression vector mediate inhibition of taco expression in macrophage,” Oligonucleotides, vol. 20,2, pp.61-8, April 2010.

Y. Chen, Y. J. Ji, R Roxby and C. Conrad, “In vivo expression of single-strand DNA in mammalian cells with DNA enzyme sequences targed to C-raf,” Antisense & nucleic acid drug development, vol 10(6), pp. 415–422, December 2000.

Y. Chen, “A novel single-stranded DNA expression vector,” Expert opinion on biological therapy, vol 2(7), pp. 735–740, October 2002.

H. W. McMicken, P. J. Bates and Y. Chen, “Antiproliferative activity of G-quartet- containing oligonucleotides generated by a novel single-stranded DNA expression system,” Cancer Gene Ther 10, pp. 867–869, December 2003.

Y. Chen and H. W. McMicken, “Intracellular production of DNA enzyme by a novel single stranded DNA expression vector,” Gene Ther 10, pp. 1776–1780, August 2003.

Y. Chen, Y-J. Ji and C. Conrad, “Expression of ssDNA in mammalian cells,” BioTechniques vol. 34,1, pp. 167-71, January 2003.

X-X Tan, K. Rose, W. Margolin and Y. Chen, “DNA Enzyme generated by a novel single-stranded DNA expression vector inhibits expression of the essential bacterial cell division gene ftsZ,” Biochemistry, 43(4), pp. 1111–1117, Ferbruary 2004.

S. Matsuzaki, M. Rashel, J. Uchiyama, S. Sakurai, T. Ujihara, M. Kuroda, et al. “Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases,” Journal of infection and chemotherapy: official journal of the Japan Society of Chemotherapy, 11(5), pp. 211–219, October 2005.

R.S. Dias (2011), “Isolamento, purificação e caracterização molecular de bacteriófagos específicos para Escherichia coli causadora de mastite bovina,” Doctoral thesis, Universidade Federal de Viçosa, Viçosa, June 2011.

R. M. Carlton, “Phage therapy: past history and future prospects,” Archivum immunologiae et therapiae experimentalis, 47(5), pp. 267–274, 1999.

A. Sulakvelidze, Z. Alavidze and J. G. Morris Jr., “Bacteriophage therapy,” Antimicrobial Agents and Chemotherapy, 45 (3), pp. 649-659, March 2001.

H. Brüssow, “What is needed for phage therapy to become a reality in Western medicine?,” Virology, 434(2), pp. 138–142, December 2012.

Z. Wan and N. L. Goddard, “Competition between conjugation and M13 phage infection in Escherichia coli in the absence of selection pressure: a kinetic study,” G3 (Bethesda, Md.) vol. 2,10, pp. 1137-44, October 2012.

A. Lin, J. Jimenez, J. Derr, P. Vera, M. L. Manapat, K. M. Esvelt, et al. “Inhibition of bacterial conjugation by phage m13 and its protein g3p: quantitative analysis and model,” PLoS One 6: e19991, May 2011.

O. Mirochnitchenko, S. Inouye and M. Inouye, “Production of single-stranded DNA in mammalian cells by means of a bacterial retron,” The Journal of biological chemistry, 269(4), pp. 2380–2383, January 1994.

C. Rader, P. Steinberg and C. F. Barbas III, “Selection from antibody libraries”, in Phage Display – A laboratory manual, 1a Edition. New York: Cold Spring Harbor Laboratory Press, 2000, pp. 10.1-10.9.

A. Telesnitsky, S. W. Blain, and S. P. Goff, “Defects in Moloney murine leukemia virus replication caused by a reverse transcriptase mutation modeled on the structure of Escherichia coli RNase,” Journal of virology vol. 66,2, pp. 615-22, February 1992.

J. Stricker and H. P. Erickson, “In vivo characterization of Escherichia coli ftsZ mutants: Effects on Z-ring structure and function,” Journal of Bacteriology, 185 (16), pp. 4796-4805, August 2003.

E. Galli and K. Gerdes, “FtsZ-ZapA-ZapB interactome of Escherichia coli,” Journal of Bacteriology, 194 (2), pp. 292-302, December 2011.

G. Charbon, M. T. Cabeen and C. Jacobs-Wagner, “Bacterial intermediate filaments: in vivo assembly, organization, and dynamics of crescentin,” Genes Dev. 23, pp. 1131–1144, 2009.

M. T. Cabeen, G. Charbon, W. Vollmer, P. Born, N. Ausmees, D. B. Weibel, et al. “Bacterial cell curvature through mechanical control of cell growth,” The EMBO journal, vol. 28(9), pp. 1208–1219, March 2009.

Y. Li, J. Hsin, L. Zhao, Y. Cheng, W. Shang, K. C. Huang, et al. “FtsZ protofilaments use a hinge-opening mechanism for constrictive force generation,” Science, Vol 341, Issue 6144, July 2013.

F. Chang and K. C. Huang, “How and why cells grow as rods,” BMC Biol 12, 54, August 2014.

J. Wagstaff and J. Löwe, “Prokaryotic cytoskeletons: protein filaments organizing small cells,” Nat Rev Microbiol 16, pp. 187–201, April 2018.

A. Feucht and J. Errington, “ftsZ mutations affecting cell division frequency, placement and morphology in Bacillus subtilis,” Microbiology (Reading, England), 151(Pt 6), pp. 2053–2064, June 2005.

G. Lan, B. R. Daniels, T. M. Dobrowsky, D. Wirtz, and S. X. Sun, “Condensation of FtsZ filaments can drive bacterial cell division,” Proceedings of the National Academy of Sciences, 106 (1), pp. 121-126, January 2009.

S. Schubert, P. Darlu, O. Clermont, A. Wieser, G. Magistro, C. Hoffmann, et al. “Role of intraspecies recombination in the spread of pathogenicity islands within the Escherichia coli species,” PLoS Pathog. 2009; 5: e1000257, January 2009.

##plugins.themes.bootstrap3.article.details##

How to Cite
Oliveira, H. V. C., Astolfi-Filho, S., & Andrade, E. V. (2021). Constructing a DNAzyme Delivery and Expression System for Escherichia coli: A Prototype for Phage Therapy. European Journal of Biology and Biotechnology, 2(2), 19-25. https://doi.org/10.24018/ejbio.2021.2.2.158